Connect Biopharma (NASDAQ:CNTB) and Legend Biotech (NASDAQ:LEGN) Head-To-Head Review

Connect Biopharma (NASDAQ:CNTB) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations and price targets for Connect Biopharma and Legend Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	7	0	2.75
Legend Biotech	1	5	9	0	2.53

Connect Biopharma presently has a consensus target price of $6.14, suggesting a potential upside of 554.19%. Legend Biotech has a consensus target price of $55.79, suggesting a potential upside of 194.46%. Given Connect Biopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Connect Biopharma is more favorable than Legend Biotech.

Profitability

This table compares Connect Biopharma and Legend Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Legend Biotech	-7.21%	-8.71%	-5.40%

Insider and Institutional Ownership

58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Connect Biopharma and Legend Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$2.95 million	20.02	-$55.48 million	($1.19)	-0.79
Legend Biotech	$1.27 billion	2.89	-$296.80 million	($0.25)	-75.78

Connect Biopharma has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Connect Biopharma has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.